Thursday, December 10, 2026 | 14:00 GMT | 15:00 CET | 09:00 EST | 06:00 PST

In difficult-to-treat Gram-negative infections, the value of antimicrobial susceptibility testing (AST) lies not only in how quickly a result is generated, but in whether that result is reliable, clinically meaningful, and available in time to inform treatment decisions.

As antimicrobial resistance (AMR) continues to limit treatment options, laboratories and clinicians increasingly need to balance analytical performance, interpretability, clinical validity, and turnaround time. Faster AST alone is not necessarily better AST. The challenge is ensuring susceptibility information can be trusted, appropriately interpreted, and translated into timely clinical action.

So, how can better and faster susceptibility information support more informed treatment decisions, particularly when managing resistant infections and considering newer or last-resort antibiotics?

Bringing together expertise in clinical microbiology, AST evaluation, infectious and tropical diseases, and molecular microbiology, this SelectScience® webinar will explore the evolving role of susceptibility testing in the AMR era, from generating reliable results to ensuring they reach the right people and inform the right clinical decisions.

Certificate of attendance

If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.

SelectScience is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.®

Webinar details

  • Format: Webinar plus extended Q&A discussion session
  • Cost: Free to attend
  • Location: Online
  • Duration: 60 minutes

Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on-demand recording once it becomes available.

Who should attend?

This event is perfect for:

  • Clinical microbiologists and laboratory managers
  • Clinicians and antimicrobial stewardship teams
  • Hospital administrators and healthcare leaders
  • Researchers and diagnostic technology developers

What will this webinar cover?

  • How increasing AMR is changing clinical decision-making in difficult-to-treat Gram-negative infections and the role of AST in supporting treatment selection.
  • The balance between analytical reliability, clinical interpretability, and turnaround time when delivering clinically actionable susceptibility results.
  • How newer and last-resort antibiotics, including cefiderocol, illustrate the growing importance of robust and appropriately interpreted susceptibility testing.
  • Opportunities to strengthen communication and collaboration between microbiology laboratories and clinicians so that susceptibility information can translate into timely clinical action.

Join the webinar to get answers to these questions:

  • How is rising AMR changing treatment decisions in difficult-to-treat Gram-negative infections?
  • What makes a susceptibility result reliable, interpretable, and clinically actionable?
  • How should laboratories and clinicians balance analytical performance with the need for faster turnaround times?
  • How can timely susceptibility information support better-informed antimicrobial treatment decisions?
  • What can antibiotics such as cefiderocol tell us about the growing importance of robust and appropriately interpreted AST?
  • What communication, workflow, and implementation gaps need to be addressed to translate susceptibility results into clinical action?

 

Dr. Muhammad Alì Muslimani
Dr. Muhammad Alì Muslimani

Physician and Researcher,

University of Pavia and the Division of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia

Dr. Muhammad Alì Muslimani is a physician and researcher affiliated with the Department of Internal Medicine and Medical Therapy at the University of Pavia and the Division of Infectious Diseases at Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. His clinical and research interests encompass infectious and tropical diseases, with a particular focus on the diagnosis and management of complex infections and the provision of interdisciplinary patient care. His experience offers valuable insight into the role of targeted laboratory investigations in informing clinical decision-making, as well as the importance of timely, evidence-based antimicrobial treatment strategies.
Christer Malmberg, PhD
Christer Malmberg, PhD

Chief Scientific Officer,

Gradientech

Christer Malmberg is a clinical microbiology and antimicrobial resistance researcher with extensive experience in rapid phenotypic antimicrobial susceptibility testing (AST). Since joining Gradientech in 2014, he has played a key role in the development, clinical evaluation and implementation of the company’s microfluidic rapid AST technology. His research focuses on accelerating reliable phenotypic susceptibility testing and understanding how earlier, clinically actionable results can support more timely antimicrobial treatment decisions. His work includes multicenter clinical evaluation of rapid AST, laboratory workflow implementation, multidrug-resistant Gram-negative infections and susceptibility testing of newer antibiotics such as cefiderocol. As Chief Scientific Officer, Christer provides scientific leadership in the continued development and clinical application of rapid AST technologies. He holds a PhD in Medical Cell Biology and an MSc in Molecular Biotechnology Engineering from Uppsala University.
Prof. Dr. Holger Rohde
Prof. Dr. Holger Rohde

Senior Physician and Deputy Director of the Institute of Medical Microbiology,

Virology and Hygiene University Medical Center Hamburg-Eppendorf (UKE)

Prof. Holger Rohde is a Senior Physician and Deputy Director of the Institute of Medical Microbiology, Virology and Hygiene at the University Medical Center Hamburg-Eppendorf (UKE), Germany, where he is also Professor of Molecular Medical Microbiology. His research spans antimicrobial resistance, hospital-acquired infections and the molecular pathogenesis of biofilm-associated infections, with expertise extending to multidrug-resistant Gram-negative pathogens and innovative diagnostic technologies. He has extensive experience in the clinical evaluation and implementation of rapid diagnostics, including rapid AST for Gram-negative bloodstream infections. Professor Rohde is currently ESCMID AMR Action Director, leading the AMR Action Subcommittee and contributing to the development and coordination of ESCMID's activities in antimicrobial resistance.

Register

Note: By completing this form, you will receive a free membership to SelectScience® and The Scientists’ Channel®. SelectScience is a trade organisation, we do not provide services to consumers and membership is for business purposes only. As a member you must provide us with a corporate email address to enable us (and our advertisers and sponsors) to contact you for marketing purposes. You can opt-out of marketing at any time. See our Privacy Policy

(*) denotes required form field(s)

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

* Required Fields